查看文章

analyses, which are subject to both type I and type II error, should be interpreted cautiously. Initiation of study drug up to 5 years after the index event is significantly beyond the high-risk period for stroke recurrence. At this time, the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study remains a more relevant trial of these therapies in patients with cerebrovascular disease. 3 The CHARISMA trial showed no benefit for combined use of aspirin and clopidogrel for stroke prevention in patients with prior history of ischemic stroke. Limited-duration combination clopidogrel and aspirin therapy is indicated in patients with recent coronary events and/or prior vascular stenting, however, and the reader is referred to the latest American College of Cardiology/AHA guidelines for information on aspirin and clopidogrel for coronary indications.